{"transactions":[{"id":747736,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T20:15:25.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":7433,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":7433,"derivative":{"exercise_price":10.5,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":7433},"source":{"system":"sec-edgar","filing":"0001261974-26-000005","document":"form4-06052026_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000126197426000005/form4-06052026_040605.xml","form_type":"4"}},{"id":747735,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-05T20:15:25.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":7142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":12392,"source":{"system":"sec-edgar","filing":"0001261974-26-000005","document":"form4-06052026_040605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000126197426000005/form4-06052026_040605.xml","form_type":"4"}},{"id":858464,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32229,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.44,"underlying":"Common Stock","underlying_shares":32229},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858463,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7650,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":9.76,"underlying":"Common Stock","underlying_shares":7650},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858462,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4561,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":37.04,"underlying":"Common Stock","underlying_shares":4561},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858461,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1072,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":71.84,"underlying":"Common Stock","underlying_shares":1072},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858460,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1618,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":167.44,"underlying":"Common Stock","underlying_shares":1618},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858459,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":560,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":146.8,"underlying":"Common Stock","underlying_shares":560},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858458,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1063,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":109.12,"underlying":"Common Stock","underlying_shares":1063},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858457,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":484,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":175.92,"underlying":"Common Stock","underlying_shares":484},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858456,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":938,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":154.4,"underlying":"Common Stock","underlying_shares":938},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858455,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":478,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":177.6,"underlying":"Common Stock","underlying_shares":478},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858454,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":938,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":226.16,"underlying":"Common Stock","underlying_shares":938},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858453,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":498,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":170.16,"underlying":"Common Stock","underlying_shares":498},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858452,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2813,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"The number of shares underlying this option and the exercise price were adjusted to reflect the 1-for-8 reverse stock split effected by the Issuer on June 16, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, each stock option that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was accelerated and became fully vested and exercisable as of immediately prior to the Effective Time. At the Effective Time, each stock option that was outstanding and unexercised as of immediately before the Effective Time and which had a per share exercise price that was (a) less than Offer Price, was cancelled and converted solely into the right to receive cash in an amount equal to the product of (i) the total number of shares subject to such stock option immediately prior to the Effective Time, multiplied by (ii) the excess of (x) the Offer Price, over (y) the exercise price payable per share under such stock option, and (b) greater than the Offer Price, was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":220.24,"underlying":"Common Stock","underlying_shares":2813},"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":858451,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-05T14:03:18.000Z","date":"2026-03-03","kind":"other","planned":false,"acquired":false,"shares":4956,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, previously granted to the Reporting Person and reported on Form 4 dated February 2, 2026, which were scheduled to fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Issuer entered into an Agreement and Plan of Merger, dated January 19, 2026 (the \"Merger Agreement\") with GlaxoSmithKline LLC, a Delaware limited liability company (\"Parent\"), Redrose Acquisition Co., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") and solely for purposes of providing a guaranty pursuant to Section 8.11 of the Merger Agreement, GSK plc, a public limited company organized under the laws of England and Wales. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, for $58.00 per share (the \"Offer Price\"), in cash, without interest and subject to any applicable withholding of taxes. On March 3, 2026, Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent (the effective time of such merger, the \"Effective Time\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F4","text":"This Form 4 reports securities transacted pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each RSU award that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive cash in an amount equal to (i) the total number of Shares issuable in settlement of such RSU immediately prior to the Effective Time without regard to vesting, multiplied by (ii) the Offer Price, which amount shall be paid in accordance with the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001261974-26-000003","document":"form4-03052026_020314.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000003/form4-03052026_020314.xml","form_type":"4"}},{"id":924952,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-02T22:53:34.000Z","date":"2026-01-30","kind":"grant","planned":false,"acquired":true,"shares":4956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents the annual grant of restricted stock units (\"RSUs\") under the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as currently in effect, which fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of common stock upon vesting."}],"balance_after":4956,"source":{"system":"sec-edgar","filing":"0001261974-26-000002","document":"form4-02022026_100231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000126197426000002/form4-02022026_100231.xml","form_type":"4"}},{"id":951647,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:32:41.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This grant vests in full upon the earlier of (i) June 10, 2026 or (ii) the date of the next annual meeting of the Company's stockholders."}],"balance_after":90000,"derivative":{"exercise_price":5.17,"expiration_date":"2036-01-02","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001171843-26-000055","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326000055/ownership.xml","form_type":"4"}},{"id":1106108,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T23:43:42.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 18, 2026,  or (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date."}],"balance_after":77397,"source":{"system":"sec-edgar","filing":"0000950170-25-088062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000095017025088062/ownership.xml","form_type":"4"}},{"id":1119400,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-06T20:15:10.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":10500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10500,"derivative":{"exercise_price":14.82,"expiration_date":"2035-06-03","underlying":"Common Stock","underlying_shares":10500},"source":{"system":"sec-edgar","filing":"0001415889-25-015974","document":"form4-06062025_040606.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000141588925015974/form4-06062025_040606.xml","form_type":"4"}},{"id":1119399,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-06T20:15:10.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":5250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. The RSUs fully vest on the earlier of (A) June 4, 2026 and (B) the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":5250,"source":{"system":"sec-edgar","filing":"0001415889-25-015974","document":"form4-06062025_040606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000141588925015974/form4-06062025_040606.xml","form_type":"4"}},{"id":1127664,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-06-02T21:04:43.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":257832,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest in 12 equal monthly installments from date of grant of May 29, 2025."}],"balance_after":257832,"derivative":{"exercise_price":0.93,"expiration_date":"2035-05-28","underlying":"Common Stock","underlying_shares":257832},"source":{"system":"sec-edgar","filing":"0001415889-25-015224","document":"form4-06022025_090639.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000141588925015224/form4-06022025_090639.xml","form_type":"4"}},{"id":1183455,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-04-03T00:40:32.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":61202,"price":1.0621,"value":65002.6442,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $65,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2025 with the first installment vesting on March 31, 2025, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":61202,"derivative":{"exercise_price":1.22,"expiration_date":"2035-03-30","underlying":"Common Stock","underlying_shares":61202},"source":{"system":"sec-edgar","filing":"0001415889-25-009802","document":"form4-04032025_120429.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000141588925009802/form4-04032025_120429.xml","form_type":"4"}},{"id":1269702,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-13T22:10:43.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 11, 2025."}],"balance_after":40000,"derivative":{"exercise_price":3.65,"expiration_date":"2035-02-11","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-25-000828","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325000828/ownership.xml","form_type":"4"}},{"id":1478794,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-14T20:17:53.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock underlying a time-based restricted stock unit award (\"RSU\"). The RSU will vest as to 100% of the total number of shares on the earlier of (i) June 13, 2025, and (ii) the next Company annual meeting of stockholders, subject to the reporting person's continued service through the vesting date."}],"balance_after":53897,"source":{"system":"sec-edgar","filing":"0000950170-24-073683","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000095017024073683/ownership.xml","form_type":"4"}},{"id":1494935,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-03T20:15:12.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":46.31,"expiration_date":"2034-05-29","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-015152","document":"form4-06032024_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000141588924015152/form4-06032024_040608.xml","form_type":"4"}},{"id":1503704,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-05-23T22:13:09.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":36490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest in 12 equal monthly installments from date of grant of May 22, 2024."}],"balance_after":36490,"derivative":{"exercise_price":4.63,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":36490},"source":{"system":"sec-edgar","filing":"0001415889-24-014375","document":"form4-05232024_100502.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000141588924014375/form4-05232024_100502.xml","form_type":"4"}},{"id":1556302,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-01T22:51:45.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":8574,"price":7.58,"value":64990.92,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $65,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2024 with the first installment vesting on March 31, 2024, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":8574,"derivative":{"exercise_price":8.98,"expiration_date":"2034-03-27","underlying":"Common Stock","underlying_shares":8574},"source":{"system":"sec-edgar","filing":"0001415889-24-009606","document":"form4-04012024_100439.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000141588924009606/form4-04012024_100439.xml","form_type":"4"}},{"id":1643245,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-14T17:03:56.000Z","date":"2024-02-09","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 9, 2024."}],"balance_after":40000,"derivative":{"exercise_price":1.57,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-24-000796","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184324000796/ownership.xml","form_type":"4"}},{"id":1691560,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T01:18:49.000Z","date":"2023-12-31","kind":"grant","planned":false,"acquired":true,"shares":5995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share."}],"balance_after":37397,"source":{"system":"sec-edgar","filing":"0001209191-24-000601","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919124000601/doc4.xml","form_type":"4"}},{"id":1730212,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2023-11-24T21:00:09.000Z","date":"2023-11-21","kind":"grant","planned":false,"acquired":true,"shares":6880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee."},{"field":"security","element":"securityTitle","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."},{"field":"security","element":"securityTitle","label":"F5","text":"Each option represents the right to purchase one share of common stock at the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."}],"balance_after":6880,"derivative":{"exercise_price":0.59,"expiration_date":"2033-11-21","underlying":"Common Stock","underlying_shares":6880},"source":{"system":"sec-edgar","filing":"0001493152-23-042661","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223042661/ownership.xml","form_type":"4"}},{"id":1730211,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-11-24T21:00:09.000Z","date":"2023-11-21","kind":"grant","planned":false,"acquired":true,"shares":5820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee."},{"field":"security","element":"securityTitle","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."},{"field":"security","element":"securityTitle","label":"F3","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each restricted stock unit represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"N/A."}],"balance_after":5820,"derivative":{"underlying":"Common Stock","underlying_shares":5820},"source":{"system":"sec-edgar","filing":"0001493152-23-042661","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223042661/ownership.xml","form_type":"4"}},{"id":1766959,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-03T22:22:44.000Z","date":"2023-09-30","kind":"grant","planned":false,"acquired":true,"shares":8676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share."}],"balance_after":31402,"source":{"system":"sec-edgar","filing":"0001209191-23-051691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919123051691/doc4.xml","form_type":"4"}},{"id":1835599,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-05T21:26:00.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":4916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share."}],"balance_after":22726,"source":{"system":"sec-edgar","filing":"0001209191-23-041218","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919123041218/doc4.xml","form_type":"4"}},{"id":1854103,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-15T22:35:28.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 14, 2024 or (b) the day before the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date."}],"balance_after":50000,"derivative":{"exercise_price":3.55,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-037544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919123037544/doc4.xml","form_type":"4"}},{"id":1857106,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2023-06-13T22:44:05.000Z","date":"2023-06-11","kind":"grant","planned":false,"acquired":true,"shares":12160,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents partial compensation for services as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 5,160 common stock purchase options as a discretionary grant."},{"field":"security","element":"securityTitle","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."},{"field":"security","element":"securityTitle","label":"F5","text":"Each option represents the right to purchase one share of common stock at the exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."}],"balance_after":12160,"derivative":{"exercise_price":1.6,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":12160},"source":{"system":"sec-edgar","filing":"0001493152-23-021132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223021132/ownership.xml","form_type":"4"}},{"id":1857105,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-13T22:44:05.000Z","date":"2023-06-11","kind":"grant","planned":false,"acquired":true,"shares":5100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents partial compensation for services as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 5,160 common stock purchase options as a discretionary grant."},{"field":"security","element":"securityTitle","label":"F3","text":"Each restricted stock unit represents the right to receive one share of common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."},{"field":"shares","element":"transactionShares","label":"F3","text":"Each restricted stock unit represents the right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The grants vest fully on the one (1) year anniversary of the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"N/A"}],"balance_after":5100,"derivative":{"underlying":"Common Stock","underlying_shares":5100},"source":{"system":"sec-edgar","filing":"0001493152-23-021132","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000149315223021132/ownership.xml","form_type":"4"}},{"id":1862037,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-08T20:41:42.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":10000,"derivative":{"exercise_price":48.79,"expiration_date":"2033-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-035450","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919123035450/doc4.xml","form_type":"4"}},{"id":1878148,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-25T22:53:22.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":12940,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest on the earlier of (i) May 24, 2024, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2024, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":12940,"derivative":{"exercise_price":20.93,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":12940},"source":{"system":"sec-edgar","filing":"0001209191-23-032287","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919123032287/doc4.xml","form_type":"4"}},{"id":1893321,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-16T01:11:20.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":5503,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person has elected to receive fully vested shares of the Issuer's common stock in lieu of cash retainer fees payable for service on the Issuer's Board of Directors and any committees thereof. The number of shares issued represents the quotient of (A) the amount of such fees divided by (B) the Issuer's closing stock price on the date such fees would otherwise be paid, rounded up to the nearest whole share."}],"balance_after":17810,"source":{"system":"sec-edgar","filing":"0001209191-23-029631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919123029631/doc4.xml","form_type":"4"}},{"id":1922297,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-11T00:02:20.000Z","date":"2023-03-31","kind":"grant","planned":false,"acquired":true,"shares":4477,"price":14.52,"value":65006.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $65,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2023 with the first installment vesting on March 31, 2023, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":4477,"derivative":{"exercise_price":18.35,"expiration_date":"2033-03-30","underlying":"Common Stock","underlying_shares":4477},"source":{"system":"sec-edgar","filing":"0001209191-23-023943","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919123023943/doc4.xml","form_type":"4"}},{"id":2024830,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-09T21:31:05.000Z","date":"2023-02-08","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over 48 substantially equal monthly installments starting March 8, 2023."}],"balance_after":40000,"derivative":{"exercise_price":3.93,"expiration_date":"2033-02-07","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001171843-23-000854","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184323000854/ownership.xml","form_type":"4"}},{"id":2227335,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T23:50:30.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the total number of shares subject to the option shall vest and become exercisable on the earlier of (a) June 16, 2023 or (b) the next annual meeting of stockholders, subject to the reporting person continuing to provide services through the vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.48,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038169","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919122038169/doc4.xml","form_type":"4"}},{"id":2244223,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2022-06-03T20:26:37.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":8293,"derivative":{"exercise_price":32.95,"expiration_date":"2032-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-22-034044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919122034044/doc4.xml","form_type":"4"}},{"id":2255272,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-26T22:07:19.000Z","date":"2022-05-25","kind":"grant","acquired":true,"shares":8500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest on the earlier of (i) May 25, 2023, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2023, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":8500,"derivative":{"exercise_price":13.64,"expiration_date":"2032-05-24","underlying":"Common Stock","underlying_shares":8500},"source":{"system":"sec-edgar","filing":"0001209191-22-032314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919122032314/doc4.xml","form_type":"4"}},{"id":2288801,"issuer":{"id":5614,"kind":"organization","name":"Compass Therapeutics, Inc.","symbol":"CMPX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-28T17:52:03.000Z","date":"2022-04-26","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in substantially equal monthly installments over four years."}],"balance_after":45000,"derivative":{"exercise_price":1.51,"expiration_date":"2032-04-25","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001171843-22-002948","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184322002948/ownership.xml","form_type":"4"}},{"id":2308317,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-04T22:05:09.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":3868,"price":16.8,"value":64982.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $65,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2022 with the first installment vesting on March 31, 2022, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":3868,"derivative":{"exercise_price":21.99,"expiration_date":"2032-03-30","underlying":"Common Stock","underlying_shares":3868},"source":{"system":"sec-edgar","filing":"0001209191-22-022629","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919122022629/doc4.xml","form_type":"4"}},{"id":2345782,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-03-09T01:06:20.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":5077,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5077,"derivative":{"exercise_price":80.42,"exercise_date":"2023-03-07","expiration_date":"2032-03-07","underlying":"Common Stock","underlying_shares":5077},"source":{"system":"sec-edgar","filing":"0001209191-22-017352","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122017352/doc4.xml","form_type":"4"}},{"id":2345781,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-09T01:06:20.000Z","date":"2022-03-07","kind":"grant","acquired":true,"shares":2953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 7, 2023."}],"balance_after":12356,"source":{"system":"sec-edgar","filing":"0001209191-22-017352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919122017352/doc4.xml","form_type":"4"}},{"id":2404152,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-02-10T23:02:59.000Z","date":"2021-11-18","kind":"grant","acquired":true,"shares":48340,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares of Common Stock subject to the Option shall vest on each quarterly anniversary of the grant date over a one-year period."}],"balance_after":48340,"derivative":{"exercise_price":2.32,"expiration_date":"2032-11-17","underlying":"Common Stock","underlying_shares":48340},"source":{"system":"sec-edgar","filing":"0001209191-22-008562","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000120919122008562/doc4.xml","form_type":"4"}},{"id":2474326,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-12-15T01:02:30.000Z","date":"2021-12-10","kind":"exercise","acquired":false,"shares":967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The third out of three annual equal installments of restricted stock units vested on December 10, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The third out of three annual equal installments of restricted stock units vested on December 10, 2021."}],"balance_after":0,"derivative":{"exercise_date":"2021-12-10","underlying":"Common Stock","underlying_shares":967},"source":{"system":"sec-edgar","filing":"0001209191-21-069638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919121069638/doc4.xml","form_type":"4"}},{"id":2474325,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-15T01:02:30.000Z","date":"2021-12-10","kind":"exercise","acquired":true,"shares":967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."}],"balance_after":9403,"source":{"system":"sec-edgar","filing":"0001209191-21-069638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919121069638/doc4.xml","form_type":"4"}},{"id":2655858,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-25T00:16:34.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest on the earlier of (i) May 28, 2022, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2022, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":7500,"derivative":{"exercise_price":19.3,"expiration_date":"2031-05-27","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001593968-21-001694","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000159396821001694/primary_01.xml","form_type":"4"}},{"id":2665989,"issuer":{"id":879,"kind":"organization","name":"BioAtla, Inc.","symbol":"BCAB"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T01:32:53.000Z","date":"2021-06-15","kind":"grant","acquired":true,"shares":12307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the total number of shares subject to the Option shall vest and become exercisable on the earlier of (a) June 15, 2022 or (b) the next annual meeting of stockholders, subject to the Optionee continuing to provide services to the Company through the vesting date; provided however, that if the Optionee ceases to provide services to the Company prior to the vesting date for any reason other than Cause (as defined in the Plan), such Option will vest on a pro-rata basis determined by multiplying the total number of shares by a fraction, the numerator of which is the number of whole months that the Optionee provided services to the Company since the date that the award was granted, and the denominator of which is 12 months."}],"balance_after":12307,"derivative":{"exercise_price":39.64,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":12307},"source":{"system":"sec-edgar","filing":"0001209191-21-041224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919121041224/doc4.xml","form_type":"4"}},{"id":2682854,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-03T21:30:17.000Z","date":"2021-06-01","kind":"grant","acquired":true,"shares":8293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be\nfully vested on the date of Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through\neach such date."}],"balance_after":8293,"derivative":{"exercise_price":51.48,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":8293},"source":{"system":"sec-edgar","filing":"0001209191-21-037791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919121037791/doc4.xml","form_type":"4"}},{"id":2739507,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-04-26T23:53:48.000Z","date":"2021-04-01","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22."},{"field":"security","element":"securityTitle","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22."}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001171843-21-002777","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000117184321002777/ownership.xml","form_type":"4"}},{"id":2761383,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-02T15:16:27.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":3822,"price":15.7002,"value":60006.1644,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $60,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2021 with the first installment vesting on March 31, 2021, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":3822,"derivative":{"exercise_price":22.2,"expiration_date":"2031-03-30","underlying":"Common Stock","underlying_shares":3822},"source":{"system":"sec-edgar","filing":"0001593968-21-001066","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000159396821001066/primary_01.xml","form_type":"4"}},{"id":2807357,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-06T01:03:40.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":5518,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":5518,"derivative":{"exercise_price":87.11,"exercise_date":"2022-03-03","expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":5518},"source":{"system":"sec-edgar","filing":"0001209191-21-018417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919121018417/doc4.xml","form_type":"4"}},{"id":2807356,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-06T01:03:40.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":2726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022."}],"balance_after":8436,"source":{"system":"sec-edgar","filing":"0001209191-21-018417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919121018417/doc4.xml","form_type":"4"}},{"id":2935982,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-21T21:43:47.000Z","date":"2020-12-17","kind":"grant","acquired":true,"shares":16587,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on March 17, 2021, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":16587,"derivative":{"exercise_price":82.74,"expiration_date":"2030-12-16","underlying":"Common Stock","underlying_shares":16587},"source":{"system":"sec-edgar","filing":"0001209191-20-064654","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000120919120064654/doc4.xml","form_type":"4"}},{"id":2950765,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-12-11T01:24:44.000Z","date":"2020-12-10","kind":"exercise","acquired":false,"shares":967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The second out of three annual equal installments of restricted stock units vested on December 10, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The second out of three annual equal installments of restricted stock units vested on December 10, 2020."}],"balance_after":967,"derivative":{"exercise_date":"2020-12-10","underlying":"Common Stock","underlying_shares":967},"source":{"system":"sec-edgar","filing":"0001209191-20-062809","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919120062809/doc4.xml","form_type":"4"}},{"id":2950764,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-11T01:24:44.000Z","date":"2020-12-10","kind":"exercise","acquired":true,"shares":967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."}],"balance_after":5710,"source":{"system":"sec-edgar","filing":"0001209191-20-062809","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919120062809/doc4.xml","form_type":"4"}},{"id":3104337,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-19T21:40:54.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest on the earlier of (i) June 18, 2021, or (ii) one day prior to the date of the Issuer's next annual meeting of stockholders to be held in 2021, subject to the Reporting Person's continuous service through each applicable vesting date."}],"balance_after":7500,"derivative":{"exercise_price":28.27,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-20-038009","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919120038009/doc4.xml","form_type":"4"}},{"id":3180534,"issuer":{"id":5803,"kind":"organization","name":"PALISADE BIO, INC.","symbol":"PALI"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2020-04-07T21:31:03.000Z","date":"2020-04-03","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21."},{"field":"security","element":"securityTitle","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"N/A"}],"balance_after":6000,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001171843-20-002463","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1357459/000117184320002463/ownership.xml","form_type":"4"}},{"id":3186701,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-04-02T22:32:02.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":3984,"price":15.06,"value":59999.04,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $60,000."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2020 with the first installment vesting on March 31, 2020, provided that the reporting person is in service as a director on each such vesting date."}],"balance_after":3984,"derivative":{"exercise_price":21.27,"expiration_date":"2030-03-30","underlying":"Common Stock","underlying_shares":3984},"source":{"system":"sec-edgar","filing":"0001209191-20-022791","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919120022791/doc4.xml","form_type":"4"}},{"id":3242239,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2020-02-29T01:07:17.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":3685,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3685,"derivative":{"exercise_price":114.47,"exercise_date":"2021-02-28","expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":3685},"source":{"system":"sec-edgar","filing":"0001209191-20-014239","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919120014239/doc4.xml","form_type":"4"}},{"id":3242238,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-29T01:07:17.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":2075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Reporting Person was granted restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on February 28, 2021."}],"balance_after":4743,"source":{"system":"sec-edgar","filing":"0001209191-20-014239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919120014239/doc4.xml","form_type":"4"}},{"id":3347330,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-12-11T00:59:30.000Z","date":"2019-12-10","kind":"exercise","acquired":false,"shares":967,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The first out of three annual equal installments of restricted stock units vested on December 10, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The first out of three annual equal installments of restricted stock units vested on December 10, 2019."}],"balance_after":1934,"derivative":{"exercise_date":"2019-12-10","underlying":"Common Stock","underlying_shares":967},"source":{"system":"sec-edgar","filing":"0001209191-19-059953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119059953/doc4.xml","form_type":"4"}},{"id":3347329,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-12-11T00:59:30.000Z","date":"2019-12-10","kind":"exercise","acquired":true,"shares":967,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."}],"balance_after":2668,"source":{"system":"sec-edgar","filing":"0001209191-19-059953","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119059953/doc4.xml","form_type":"4"}},{"id":3349818,"issuer":{"id":62554,"kind":"organization","name":"RAPT Therapeutics, Inc.","symbol":"RAPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-06T22:56:04.000Z","date":"2019-12-04","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Option shall vest in a series of three successive equal annual installments over the three-year period measured from the date of grant."}],"balance_after":22500,"derivative":{"exercise_price":27.53,"expiration_date":"2029-12-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-19-059521","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1673772/000120919119059521/doc4.xml","form_type":"4"}},{"id":3620931,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2019-03-05T01:04:26.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":3213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option will vest at a rate of 1/24th of the total option amount granted on a monthly basis over two years commencing on the first monthly anniversary of the Issuer's 2019 Annual Meeting of Stockholders."}],"balance_after":3213,"derivative":{"exercise_price":145.48,"expiration_date":"2029-03-04","underlying":"Common Stock","underlying_shares":3213},"source":{"system":"sec-edgar","filing":"0001209191-19-016032","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119016032/doc4.xml","form_type":"4"}},{"id":3620930,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-03-05T01:04:26.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":1633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents the right to receive one share of common stock and will vest in full on the first year anniversary of the Issuer's 2019 Annual Meeting of Stockholders."}],"balance_after":1701,"source":{"system":"sec-edgar","filing":"0001209191-19-016032","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919119016032/doc4.xml","form_type":"4"}},{"id":3736749,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-12-11T13:38:27.000Z","date":"2018-12-10","kind":"grant","acquired":true,"shares":2901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Sarepta Therapeutics, Inc. common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in three equal annual installments beginning December 10, 2019, subject to continued service to the Board."}],"balance_after":2901,"derivative":{"expiration_date":"2028-12-10","underlying":"Common Stock","underlying_shares":2901},"source":{"system":"sec-edgar","filing":"0001209191-18-061908","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118061908/doc4.xml","form_type":"4"}},{"id":3736748,"issuer":{"id":4426,"kind":"organization","name":"Sarepta Therapeutics, Inc.","symbol":"SRPT"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (right to buy)","published_at":"2018-12-11T13:38:27.000Z","date":"2018-12-10","kind":"grant","acquired":true,"shares":5711,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in three equal annual installments beginning December 10, 2019, subject to continued service to the Board."}],"balance_after":5711,"derivative":{"exercise_price":122.8,"expiration_date":"2028-12-10","underlying":"Common Stock","underlying_shares":5711},"source":{"system":"sec-edgar","filing":"0001209191-18-061908","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/873303/000120919118061908/doc4.xml","form_type":"4"}},{"id":3776692,"issuer":{"id":162645,"kind":"organization","name":"SENOMYX INC","symbol":"SNMX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-11-02T18:03:26.000Z","date":"2018-11-02","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":1.36,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-056991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1123979/000120919118056991/doc4.xml","form_type":"4"}},{"id":3776691,"issuer":{"id":162645,"kind":"organization","name":"SENOMYX INC","symbol":"SNMX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-11-02T18:03:26.000Z","date":"2018-11-02","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was cancelled in the Merger in exchange for a cash payment equal to $1.50 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger."}],"balance_after":0,"derivative":{"exercise_price":0.8985,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-18-056991","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1123979/000120919118056991/doc4.xml","form_type":"4"}},{"id":3776690,"issuer":{"id":162645,"kind":"organization","name":"SENOMYX INC","symbol":"SNMX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-02T18:03:26.000Z","date":"2018-11-02","kind":"other","acquired":false,"shares":10000,"price":1.5,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of pursuant to an Agreement and Plan of Merger (the \"Merger Agreement\"), dated September 16, 2018, among the Issuer, Firmenich Incorporated, a Delaware corporation (\"Parent\"), and Sentry Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Purchaser\") in exchange for a cash consideration of $1.50 per share, without interest, subject to any applicable withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly owned subsidiary of Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-056991","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123979/000120919118056991/doc4.xml","form_type":"4"}},{"id":3844025,"issuer":{"id":164322,"kind":"organization","name":"JUNIPER PHARMACEUTICALS INC","symbol":"JNP"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-15T16:26:24.000Z","date":"2018-08-14","kind":"disposition_to_issuer","acquired":false,"shares":16244,"price":11.5,"value":186806.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the \"Issuer\") dated as of July 2, 2018.  At the effective time of the merger (the \"Effective Time\") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the \"Offer Price\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Includes 8,910 restricted stock units that did not vest prior to the Effective Time of the merger.  Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 8,910 restricted stock units was cancelled in exchange for the Offer Price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-046798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/821995/000120919118046798/doc4.xml","form_type":"4"}},{"id":3917342,"issuer":{"id":162645,"kind":"organization","name":"SENOMYX INC","symbol":"SNMX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2018-05-25T17:00:12.000Z","date":"2018-05-24","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments beginning one month following the Date of Grant (5/24/2018)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The Reporting Person also holds outstanding options to purchase 148,750 shares of Common Stock. In addition, the Reporting Person beneficially owns 10,000 shares of common stock."}],"balance_after":20000,"derivative":{"exercise_price":1.36,"expiration_date":"2028-05-23","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-18-010752","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123979/000143774918010752/rdgdoc.xml","form_type":"4"}},{"id":4188876,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-10T21:59:12.000Z","date":"2017-10-10","kind":"grant","acquired":true,"shares":15472,"price":0.38,"value":5879.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing stock price of the Company's stock on the first trading day of the quarter."}],"balance_after":39167,"source":{"system":"sec-edgar","filing":"0001394548-17-000032","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000139454817000032/primary_doc.xml","form_type":"4"}},{"id":4261637,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-06T21:23:56.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Granted pursuant to the Issuer's 2016 Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option will vest and become exercisable in equal quarterly installments over one year beginning three months from June 8, 2017, such that the option will be fully exercisable as of June 8, 2018."}],"balance_after":5000,"derivative":{"exercise_price":0.55,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001394548-17-000021","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000139454817000021/primary_doc.xml","form_type":"4"}},{"id":4261636,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-06T21:23:56.000Z","date":"2017-07-06","kind":"grant","acquired":true,"shares":9866,"price":0.59,"value":5820.94,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Effective January 1, 2017, 33% of the cash retainer payments to our Board will be pain in unrestricted shares of the Company's common stock delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing stock price of the Company's stock on the first trading day of the quarter."}],"balance_after":23695,"source":{"system":"sec-edgar","filing":"0001394548-17-000021","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000139454817000021/primary_doc.xml","form_type":"4"}},{"id":4266245,"issuer":{"id":164322,"kind":"organization","name":"JUNIPER PHARMACEUTICALS INC","symbol":"JNP"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.01","published_at":"2017-07-05T17:50:47.000Z","date":"2017-06-30","kind":"grant","acquired":true,"shares":8910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This restricted stock unit award shall vest in full immediately prior to the 2018 annual shareholders meeting."}],"balance_after":16244,"source":{"system":"sec-edgar","filing":"0001209191-17-043449","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/821995/000120919117043449/doc4.xml","form_type":"4"}},{"id":4310251,"issuer":{"id":162645,"kind":"organization","name":"SENOMYX INC","symbol":"SNMX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2017-05-22T18:23:26.000Z","date":"2017-05-11","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in 12 equal monthly installments beginning one month following the Date of Grant (5/11/2017)."}],"balance_after":20000,"derivative":{"exercise_price":0.8985,"expiration_date":"2027-05-10","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001437749-17-009847","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123979/000143774917009847/rdgdoc.xml","form_type":"4"}},{"id":4353368,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-12T21:08:44.000Z","date":"2017-04-10","kind":"grant","acquired":true,"shares":8815,"price":0.59,"value":5200.85,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Effective January 1, 2017, 33% of the cash retainer payment to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing stock price of the Company's stock on the first trading day of the quarter."}],"balance_after":13829,"source":{"system":"sec-edgar","filing":"0001394548-17-000017","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000139454817000017/primary_doc.xml","form_type":"4"}},{"id":4371680,"issuer":{"id":162645,"kind":"organization","name":"SENOMYX INC","symbol":"SNMX"},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-03-27T17:02:21.000Z","date":"2017-03-24","kind":"purchase","acquired":true,"shares":10000,"price":1,"value":10000.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001437749-17-005335","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1123979/000143774917005335/rdgdoc.xml","form_type":"4"}},{"id":4482881,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":40876,"kind":"person","name":"GRAY MARY ANN","position":1,"cik":"0001261974","reported_name":"GRAY MARY ANN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-24T23:12:32.000Z","date":"2017-01-20","kind":"grant","acquired":true,"shares":2525,"price":1.98,"value":4999.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the closing stock price of the Company's stock on the first trading day of the quarter."}],"balance_after":5004,"source":{"system":"sec-edgar","filing":"0001394548-17-000009","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1261974/000139454817000009/primary_doc.xml","form_type":"4"}}]}